Early research suggests semaglutide — the active ingredient in Ozempic and Wegovy — may reduce cravings for alcohol, nicotine, opioids, and even compulsive behaviors like gambling. These findings are preliminary. Ozempic is not FDA-approved to treat any addiction, and no large human clinical trials have yet concluded. But the science behind the signal is real and growing.
Why Would a Diabetes Drug Affect Addiction?
The connection starts in the brain. GLP-1 receptors — the same receptors that semaglutide activates in the pancreas to regulate blood sugar — are also found in the brain's mesolimbic dopamine system, the circuit responsible for reward, motivation, and craving. Research published in Physiology & Behavior by Hajnal et al. (2010) identified GLP-1 receptor activity in the nucleus accumbens, a region central to addiction. When semaglutide activates these receptors, it appears to dampen the dopamine "rush" triggered by substances or rewarding behaviors, potentially reducing the drive to use them.
In simpler terms: the same brain pathway that makes drugs, alcohol, or food feel rewarding may be quieted by GLP-1 receptor agonists like Ozempic.
What Does the Research Actually Show?
Most evidence so far comes from animal studies and retrospective human data — not randomized controlled trials. Here is a snapshot of what researchers have found across different substances:
| Substance or Behavior | Study Type | Key Finding | Status |
|---|---|---|---|
| Alcohol | Animal model (rat) | Semaglutide reduced alcohol intake and relapse-like drinking (Klausen et al., JCI Insight, 2022) | Human trials underway |
| Nicotine / Smoking | Retrospective human data | Patients on GLP-1 agonists reported reduced smoking urges in observational studies | Early; no RCT concluded |
| Opioids | Animal model | GLP-1 agonists reduced opioid self-administration in preclinical settings | Very early; human data limited |
| Cocaine / Stimulants | Animal model | Reduced cocaine-seeking behavior observed in rodent studies | Preclinical only |
| Gambling / Compulsive behavior | Case reports | Anecdotal reports of reduced compulsive urges; no controlled data | Anecdotal only |
A narrative review by Anestis et al. in Current Psychiatry Reports (2023) noted that while animal and mechanistic data are promising, human evidence remains sparse and largely observational. Correlation is not causation — people losing weight on Ozempic may reduce drinking for lifestyle reasons unrelated to the drug's direct brain effects.
Most important takeaway: Ozempic is not approved — and should not be used — as a standalone treatment for addiction. If you or someone you know is struggling with substance use, evidence-based treatments (including counseling, FDA-approved medications like naltrexone or buprenorphine, and support programs) remain the standard of care.
What Is the Alcohol Connection, Specifically?
Alcohol has attracted the most research attention. The 2022 Klausen et al. study in JCI Insight found that semaglutide significantly reduced alcohol consumption in alcohol-preferring rats, including a reduction in relapse-like drinking after a period of abstinence. Leggio et al., writing in Neuropsychopharmacology (2022), argued that the GLP-1 system may represent a genuinely novel target for treating alcohol use disorder, noting that existing medications for AUD have limited efficacy.
Clinically, some patients on Ozempic or Wegovy have spontaneously reported drinking less — a pattern that has been widely discussed in patient communities and noted by prescribers. However, these are self-reported observations, not controlled trial results. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) is actively funding trials to investigate this effect more rigorously.
Are There Any Risks to Consider?
Even if future trials confirm a benefit, using Ozempic off-label for addiction would carry the same side effects documented in its FDA prescribing information: nausea, vomiting, diarrhea, risk of pancreatitis, and the black-box warning regarding thyroid C-cell tumors seen in animal studies. Additionally:
- Addiction is complex. Reducing a craving signal pharmacologically does not address the psychological, social, or trauma-related roots of substance use disorders.
- Drug interactions are not well studied in the context of co-occurring substance use.
- Access and cost remain significant barriers — Ozempic can exceed $900 per month without insurance coverage for an approved indication.
- Rebound effects after stopping GLP-1 agonists are not yet characterized in the addiction context.
What Comes Next in the Research?
Several clinical trials are now recruiting or in progress. The National Institutes of Health and independent academic centers are running human studies examining semaglutide's effects on alcohol use disorder and nicotine dependence. Results from these trials — likely to appear between 2025 and 2027 — will be the first rigorous test of whether the animal and observational data translate into a real therapeutic benefit for humans. Until those results are published, the promise of Ozempic for addiction remains exactly that: a promising early signal, not a proven treatment.
Frequently Asked Questions
The early science around Ozempic and addiction is genuinely exciting — but excitement is not the same as evidence. If you are currently taking a GLP-1 medication and have noticed changes in cravings or substance use, let your prescriber know. And if you are dealing with a substance use disorder, please speak with your doctor or a licensed addiction specialist about treatment options that have strong, established evidence behind them. Self-treating addiction with an off-label medication is not a safe substitute for comprehensive care.
- Klausen MK et al., 'Semaglutide reduces alcohol intake and relapse-like drinking in alcohol-preferring rats,' JCI Insight, 2022
- Anestis MD et al., 'GLP-1 receptor agonists and addictive behaviors: a narrative review,' Current Psychiatry Reports, 2023
- Hajnal A et al., 'Glucagon-like peptide-1 and reward: the role of the mesolimbic dopamine system,' Physiology & Behavior, 2010
- FDA, 'Ozempic (semaglutide) Prescribing Information,' FDA.gov, 2023
- Leggio L et al., 'GLP-1 receptor agonists as a novel pharmacotherapy for alcohol use disorder,' Neuropsychopharmacology, 2022